Literature DB >> 28765933

Gene therapy for human ovarian cancer cells using efficient expression of Fas gene combined with γδT cells.

Jiajing Lin1, Dingyuan Zeng2, Hongying He1, Guangping Tan1, Ying Lan3, Fuyan Jiang4, Shuting Sheng5.   

Abstract

Low tissue specificity and efficiency of exogenous gene expression are the two major obstacles in tumor‑targeted gene therapy. The Fas cell surface death receptor (Fas)/Fas ligand pathway is one of the primary pathways responsible for the regulation of cell apoptosis. The aim of the present study was to explore whether the regulation of tumor specific promoters and a two‑step transcriptional amplification system (TSTA) assured efficient, targeted expression of their downstream Fas gene in human ovarian cancer cells, and to assess the killing effect of γδT cells on these cells with high Fas expression. Three shuttle plasmids containing different control elements of the human telomerase reverse transcriptase (hTERT) promoter and/or TSTA were constructed and packaged into adenovirus 5 (Ad5) vectors for the expression of exogenous Fas gene. The human ovarian cancer cell line SKOV3 and a control human embryonic lung fibroblast cell line were transfected with Ad5hTERT‑Fas or Ad5hTERT‑TSTA‑Fas. Fas mRNA and protein expression were examined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. γδT lymphocytes were isolated, cultured and mixed at different ratios with SKOV3 cells with Fas expression in order to assess the killing effect of γδT cells. hTERT promoter induced the specific expression of FAS gene in SKOV3 cells, and the TSTA strategy increased FAS expression by 14.2‑fold. The killing effect of γδT cells increased with the expression level of Fas and the effector‑target cell ratio. The killing rate for SKOV3 cells with high FAS expression was 72.5% at an effector‑target cell ratio of 40:1. The regulators of hTERT promoter and TSTA assure the efficient and targeted expression of their downstream Fas gene in SKOV3 cells. The killing effect of γδT cells for ovarian cancer cells with relatively high Fas expression was improved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765933     DOI: 10.3892/mmr.2017.7107

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

1.  Therapeutic effect of targeted Fas-expressing adenoviruses method combining γδ T cells in a mouse model of human ovarian carcinoma.

Authors:  Dingyuan Zeng; Jiajing Lin; Hongying He; Guangping Tan; Ying Lan; Fuyan Jiang; Shuting Sheng
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

Review 2.  Current development in adenoviral vectors for cancer immunotherapy.

Authors:  Greyson Willis Grossman Biegert; Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Mol Ther Oncolytics       Date:  2021-11-20       Impact factor: 7.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.